^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    OSE-279

    i
    Other names: OSE-279, OSE 279, OSE279
    Associations

    News

    Trials
    Company:
    OSE Immunotherapeutics
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov)
    P1/2, N=24, Recruiting, OSE Immunotherapeutics | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: May 2024 --> Oct 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    MSI (Microsatellite instability)
    |
    OSE-279
    over1year
    Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov)
    P1/2, N=24, Recruiting, OSE Immunotherapeutics
    New P1/2 trial • Metastases
    |
    MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    OSE-279